Yu James B, McNiff Jennifer M, Lund Molly W, Wilson Lynn D
Department of Therapeutic Radiology, Yale University School of Medicine, New Haven, CT 06520-8040, USA.
Int J Radiat Oncol Biol Phys. 2008 Apr 1;70(5):1542-5. doi: 10.1016/j.ijrobp.2007.08.077. Epub 2007 Nov 26.
Primary cutaneous CD30+ anaplastic large-cell lymphoma (CALCL) is a relatively rare and indolent variant of cutaneous T-cell lymphoma (CTCL). This report examines the response of localized disease to radiation alone.
The Yale Cancer Center records were examined, and all patients with CTCL from January 1, 2001, to September 1, 2006, evaluated in the Department of Therapeutic Radiology were identified. Only those patients with localized or single CALCL lesions, no clinical evidence or history of lymphomatoid papulosis, no history of other CTCLs, no history of other skin disorders, lack of lymph node involvement, unambiguous pathology reports, and treatment with radiation alone were included.
Eight patients were identified. Median age was 67 years, and gender was split evenly. Patients received radiation ranging from 34 to 44 Gy in 2-Gy fractions. Most patients (5 of 8) received 40 Gy, using 6 to 9 MeV electrons with 0.5 to 2 cm of bolus. All patients had a complete response. All patients were without evidence of disease at the most recent follow-up (median follow-up, 12 months). Radiation therapy was well tolerated, and the only recorded toxicity was Grade I to II dermatitis.
Radiation therapy alone for localized CALCL is very well tolerated and clinical response is excellent. A dose of 40 Gy in 2-Gy fractions seems to be well tolerated and effective in inducing a complete response. Lower doses may be effective in achieving the same result, but data are not available. Longer follow-up is necessary before conclusions regarding durable disease-free survival can be made.
原发性皮肤CD30+间变性大细胞淋巴瘤(CALCL)是皮肤T细胞淋巴瘤(CTCL)中一种相对罕见且惰性的亚型。本报告研究局限性疾病单独接受放疗的反应。
查阅耶鲁癌症中心的记录,确定2001年1月1日至2006年9月1日期间在放射治疗科接受评估的所有CTCL患者。仅纳入那些患有局限性或单个CALCL病变、无淋巴瘤样丘疹的临床证据或病史、无其他CTCL病史、无其他皮肤疾病史、无淋巴结受累、病理报告明确且仅接受放疗的患者。
共确定8例患者。中位年龄为67岁,性别分布均匀。患者接受的放疗剂量为34至44 Gy,分2 Gy分次给予。大多数患者(8例中的5例)接受40 Gy,使用6至9 MeV电子线,加0.5至2 cm的填充物。所有患者均获得完全缓解。在最近一次随访时(中位随访时间为12个月),所有患者均无疾病证据。放疗耐受性良好,唯一记录到的毒性反应为I至II级皮炎。
局限性CALCL单独放疗耐受性非常好,临床反应极佳。2 Gy分次给予40 Gy的剂量似乎耐受性良好且能有效诱导完全缓解。较低剂量可能也能有效达到相同效果,但尚无相关数据。在得出关于持久无病生存的结论之前,需要更长时间的随访。